l-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter

Brain Res. 2021 Oct 1:1768:147583. doi: 10.1016/j.brainres.2021.147583. Epub 2021 Jul 17.

Abstract

Previous studies have pointed out that l-DOPA can interact with D1 or D2 receptors independent of its conversion to endogenous dopamine. The present study was set to investigate whether l-DOPA modulates dopamine release from striatal nerve terminals, using a preparation of synaptosomes preloaded with [3H]DA. Levodopa (1 µM) doubled the K+-induced [3H]DA release whereas the D2/D3 receptor agonist pramipexole (100 nM) inhibited it. The l-DOPA-evoked facilitation was mimicked by the D1 receptor agonist SKF38393 (30-300 nM) and prevented by the D1/D5 antagonist SCH23390 (100 nM) but not the DA transporter inhibitor GBR12783 (300 nM) or the aromatic l-amino acid decarboxylase inhibitor benserazide (1 µM). Higher l-DOPA concentrations (10 and 100 µM) elevated spontaneous [3H]DA efflux. This effect was counteracted by GBR12783 but not SCH23390. Binding of [3H]SCH23390 in synaptosomes (in test tubes) revealed a dense population of D1 receptors (2105 fmol/mg protein). Both SCH23390 and SKF38393 fully inhibited [3H]SCH23390 binding (Ki 0.42 nM and 29 nM, respectively). l-DOPA displaced [3H]SCH23390 binding maximally by 44% at 1 mM. This effect was halved by addition of GBR12935 and benserazide. We conclude that l-DOPA facilitates exocytotic [3H]DA release through SCH23390-sensitive D1 receptors, independent of its conversion to DA. It also promotes non-exocytotic [3H]DA release, possibly via conversion to DA and reversal of DA transporter. These data confirm that l-DOPA can directly interact with dopamine D1 receptors and might extend our knowledge of the neurobiological mechanisms underlying l-DOPA clinical effects.

Keywords: D1 receptors; Dopamine release; Dopamine transporter; SCH-23390; Synaptosomes; l-DOPA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • Animals
  • Benzazepines / pharmacokinetics
  • Benzazepines / pharmacology
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Dopamine / metabolism*
  • Dopamine Agonists / pharmacology
  • Dopamine Antagonists / pharmacology
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Levodopa / metabolism
  • Levodopa / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Receptors, Dopamine D1 / drug effects
  • Receptors, Dopamine D1 / metabolism*
  • Receptors, Dopamine D2 / drug effects
  • Receptors, Dopamine D2 / metabolism

Substances

  • Benzazepines
  • Dopamine Agonists
  • Dopamine Antagonists
  • Dopamine Plasma Membrane Transport Proteins
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • SCH 23390
  • Levodopa
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Dopamine